Last updated: October 1, 2026
Aminocaproic acid is an established generic antifibrinolytic with limited active-ingredient patent protection and low barriers to conventional formulation. Commercial differentiation depends on excipient control, dosage-form convenience, stability, sterile manufacturing, supply reliability, and targeted hospital applications. The strongest opportunities are ready-to-use oral liquids, preservative-free injectable presentations, pediatric dosing formats, institution-specific packaging, and validated compounded or topical platforms where regulatory requirements are met.
What is aminocaproic acid used for?
Aminocaproic acid is a synthetic lysine analog that inhibits plasminogen activation and reduces fibrinolysis. FDA-approved labeling identifies its use in acute bleeding associated with elevated fibrinolytic activity, including certain surgical and hematologic settings.[1]
The drug is available primarily as:
| Dosage form |
Typical strength |
Principal commercial setting |
| Injection |
250 mg/mL in commonly marketed presentations |
Hospitals, surgery, intensive care |
| Oral solution |
0.25 g/mL in commonly marketed presentations |
Hospital discharge, pediatric and adult oral therapy |
| Tablets |
Market availability varies by jurisdiction and supplier |
Outpatient oral treatment |
Aminocaproic acid is not interchangeable with tranexamic acid on a milligram-for-milligram basis. The products have different pharmacologic profiles, dosing regimens, clinical evidence bases, and market positions.
What excipients are used in aminocaproic acid formulations?
The excipient system depends on the route, concentration, container, and intended shelf life. Injectable formulations generally require a minimal composition because aminocaproic acid is highly water soluble and is administered in clinical environments where unnecessary excipients increase risk.
Injectable formulation strategy
The core injectable formulation typically includes:
- Aminocaproic acid
- Water for injection
- Sodium chloride or another tonicity-adjusting agent, depending on the product
- Hydrochloric acid or sodium hydroxide for pH adjustment
- Nitrogen or another headspace-control strategy where container oxidation risk requires it
The formulation objective is chemical stability, sterility, acceptable osmolality, low particulate burden, and compatibility with commonly used infusion systems. Benzyl alcohol and other antimicrobial preservatives should generally be avoided in neonatal, pediatric, and high-risk patient populations unless there is a clear regulatory and clinical justification.
A ready-to-use premixed infusion could reduce pharmacy preparation steps. That product would require careful evaluation of:
- Diluent compatibility
- Container adsorption
- Extractables and leachables
- Freeze-thaw and shipping stability
- Particulate formation
- In-use stability after vial puncture or bag connection
- Compatibility with common infusion pumps and tubing
The commercial value of such a product would come from workflow reduction and medication-safety benefits rather than novel pharmacology.
Oral solution excipient strategy
Oral aminocaproic acid solutions require more extensive excipient engineering. Relevant excipient functions include:
| Formulation need |
Candidate excipient classes |
| Sweetness and palatability |
Sucrose, sorbitol, sucralose, saccharin derivatives |
| Viscosity and mouthfeel |
Cellulose derivatives, xanthan gum, povidone |
| Flavor masking |
Fruit, berry, citrus, or neutral flavor systems |
| Microbial control |
Parabens, benzoates, sorbates, or preservative-free packaging |
| pH control |
Citrate, phosphate, acetate, or other buffered systems |
| Chelation |
Edetate salts where justified by stability data |
| Oxidation control |
Antioxidants only when supported by degradation data |
The preferred strategy is not to maximize excipient complexity. Aminocaproic acid has a strong taste profile that may require masking, but each additional excipient increases compatibility, tolerability, regulatory, and supply-chain risk.
A pediatric formulation should avoid ethanol, propylene glycol at excessive levels, high sugar loads, and excipients with known age-related safety concerns. A sugar-free product using sorbitol or another polyol could serve diabetic patients, but excessive polyol content may cause gastrointestinal effects. A unit-dose oral syringe format could improve dosing accuracy and reduce dependence on household measuring devices.
Tablet and solid-dose strategy
Tablets can use conventional excipients such as:
- Microcrystalline cellulose
- Lactose or another diluent
- Povidone or copovidone
- Croscarmellose sodium or sodium starch glycolate
- Magnesium stearate
- Film-coating polymers
- Plasticizers and colorants
The commercial challenge is tablet burden. Aminocaproic acid dosing can require multiple tablets, reducing adherence and limiting the value of a conventional immediate-release tablet unless the product has a strong supply or institutional advantage.
Extended-release technology is theoretically possible but has limited commercial logic without a defined clinical need. The drug’s use is often acute or short term, and an extended-release product would require new pharmacokinetic, safety, and clinical evidence.
What formulation patents protect aminocaproic acid?
Aminocaproic acid is an old active pharmaceutical ingredient. Core composition-of-matter patent protection has expired, and conventional immediate-release formulations are unlikely to have meaningful blocking patent barriers.
Potentially protectable subject matter includes:
- Novel preservative-free formulations
- Specific pH and buffer systems
- Long-term stable ready-to-use infusions
- Unit-dose oral delivery systems
- Taste-masked pediatric liquids
- Novel topical or intranasal delivery systems
- Container-closure combinations
- Manufacturing processes that materially improve impurity control
- Specific methods of use in narrowly defined patient populations
A formulation patent would need more than a routine substitution of one pharmaceutically acceptable excipient for another. Commercially relevant protection would be stronger where the formulation produces an unexpected stability, tolerability, delivery, or manufacturing result.
How many patents cover aminocaproic acid?
There is no apparent modern patent estate comparable to those surrounding newer branded drugs. The relevant intellectual-property risk is more likely to arise from a competitor’s formulation, delivery system, manufacturing process, or method-of-use patent than from the aminocaproic acid molecule itself.
A freedom-to-operate review should cover United States, European, Canadian, Japanese, and major emerging-market records. It should search both “aminocaproic acid” and “epsilon-aminocaproic acid,” together with claims directed to antifibrinolytic compositions, topical hemostasis, surgical bleeding, dental bleeding, and compounded preparations.
When does aminocaproic acid lose exclusivity?
Aminocaproic acid has already lost practical market exclusivity as an active ingredient. FDA-approved generic pathways are available, subject to product-specific requirements for dosage form, strength, route, bioequivalence, sterility, and labeling.[2]
The relevant exclusivity framework is therefore:
| Exclusivity type |
Commercial status |
| Active-ingredient patent |
Expired or commercially irrelevant |
| New chemical entity exclusivity |
Expired |
| Conventional generic entry |
Available |
| Formulation exclusivity |
Possible only for a qualifying new product |
| Method-of-use exclusivity |
Possible only for a newly approved, legally eligible indication |
| Orphan exclusivity |
Not generally associated with the conventional product |
A new formulation may qualify for regulatory exclusivity only if it meets the statutory requirements for a new drug product or indication. A formulation improvement alone does not automatically create market exclusivity.
What is the FDA regulatory and Orange Book status?
FDA-regulated aminocaproic acid products are generally positioned as legacy prescription products and generics. The Orange Book is the relevant source for current reference-listed products, therapeutic-equivalence evaluations, patents, and exclusivity listings.[2]
Commercial diligence should verify, for each target presentation:
- Reference-listed drug status
- Approved strengths and routes
- Therapeutic-equivalence rating
- Current listed manufacturers
- Active Orange Book patents, if any
- Product discontinuation status
- Approved labeling and administration requirements
- ANDA suitability
- Need for a new drug application or supplemental approval
The Orange Book should not be treated as a complete source for nonapproved topical, dental, cosmetic, or compounded uses. Such products may fall outside the conventional approved-product framework.
What generic entry risks exist for aminocaproic acid?
Generic entry risk is high for conventional products because the molecule is old and the technology is familiar. The main risk is price erosion, particularly for standard injectable vials and basic oral solutions.
The commercial risk profile differs by presentation:
| Product concept |
Generic pressure |
Differentiation potential |
| Standard injectable vial |
High |
Low |
| Standard oral solution |
High |
Moderate |
| Unit-dose oral syringe |
Moderate |
Moderate |
| Sugar-free pediatric solution |
Moderate |
Moderate to high |
| Ready-to-use infusion bag |
Moderate |
High if operational benefits are demonstrated |
| Preservative-free multidose system |
Moderate |
Moderate |
| Novel topical product |
Uncertain |
High, but regulatory risk is higher |
Paragraph IV litigation is unlikely to be a central issue for a standard aminocaproic acid ANDA unless an incumbent has listed a later-expiring formulation or method patent. The more likely competitive mechanism is simultaneous generic entry and price competition.
Which companies are challenging or supplying aminocaproic acid?
The supplier base includes generic pharmaceutical companies, contract manufacturers, hospital suppliers, and regional distributors. Market participation can change because injectable products are vulnerable to manufacturing interruptions, raw-material shortages, and limited supplier redundancy.
A commercial assessment should rank suppliers by:
- FDA approval and inspection history
- Sterile manufacturing capacity
- API source diversification
- Back-order history
- Hospital contracting access
- Packaging flexibility
- Ability to support low-volume presentations
- International registration coverage
No reliable standalone revenue figure can be assigned to aminocaproic acid without a defined market scope. Public companies generally do not report product-level sales for this mature generic. Revenue analysis should use prescription volume, hospital purchasing data, average selling price, shortage frequency, and dosage-form share.
What licensing deals and partnerships are commercially relevant?
Licensing opportunities are more likely to involve technology and distribution than the active ingredient. Attractive transaction structures include:
- Acquiring a ready-to-use sterile formulation
- Licensing a pediatric taste-masking platform
- Contracting a specialized aseptic manufacturer
- Partnering with a hospital distributor
- Licensing a unit-dose oral delivery device
- Co-developing a topical formulation for a defined regulatory pathway
- Obtaining regional rights for emerging markets
The strongest licensing target would combine formulation know-how, regulatory documentation, manufacturing capacity, and an established hospital sales channel. A simple license to aminocaproic acid itself would have limited strategic value because the molecule is widely available.
How does aminocaproic acid compare with tranexamic acid?
Tranexamic acid is the more commercially prominent antifibrinolytic in many markets. It has broader visibility in trauma, obstetrics, surgery, dentistry, and topical applications. Aminocaproic acid remains relevant where clinicians have established protocols, where supply or pricing favors it, or where a specific indication supports its use.
| Factor |
Aminocaproic acid |
Tranexamic acid |
| Molecule age |
Mature generic |
Mature generic |
| Main mechanism |
Antifibrinolytic lysine analog |
Antifibrinolytic lysine analog |
| Brand differentiation |
Limited |
Limited in generic markets |
| Hospital use |
Established but narrower in many markets |
Broad and growing in many settings |
| Pediatric liquid opportunity |
Meaningful |
Also meaningful |
| Topical opportunity |
Possible, often off-label or compounded |
More developed in some markets |
| Patent barrier |
Low |
Low for core molecule |
| Commercial leverage |
Supply, formulation, packaging |
Indication breadth and market familiarity |
Aminocaproic acid can compete where its manufacturing cost, supply reliability, dosage flexibility, or institutional familiarity creates an advantage.
What manufacturing and IP barriers matter most?
The main barriers are technical and operational rather than molecular patent barriers.
Sterile manufacturing
Injectable products require validated aseptic processing, container-closure integrity, particulate control, endotoxin control, and reliable fill-finish capacity. A supplier with redundant sterile lines can command greater value than a supplier with only an approved dossier.
API quality
Critical API attributes include assay, related substances, residual solvents, elemental impurities, microbial quality where applicable, and particle characteristics. Consistent API quality supports simpler excipient systems and reduces batch-release risk.
Packaging
Commercially useful packaging options include:
- Single-dose vials
- Ready-to-use infusion bags
- Prefilled syringes, if technically and regulatorily justified
- Unit-dose oral syringes
- Child-resistant multidose bottles
- Amber containers for light-sensitive formulations, if required by data
Geographic coverage
The United States, European Union, Canada, Japan, Australia, Latin America, and selected Asian markets have different registration, labeling, pharmacopoeial, and reimbursement requirements. A formulation that uses common compendial excipients and globally available packaging components will have a lower registration burden.
What are the best commercial opportunities?
The most defensible opportunities are:
- A preservative-free, ready-to-use injectable product for hospital use.
- A sugar-free, taste-masked oral solution for pediatric and outpatient treatment.
- Unit-dose oral syringes with clear labeling and dose-volume reduction.
- A reliable dual-source product positioned against shortages and supply interruptions.
- A specialty topical or dental product supported by a defined clinical and regulatory strategy.
- Regional licensing in markets where injectable antifibrinolytic supply is fragmented.
A conventional tablet has the weakest differentiation case unless it solves a specific availability or dosing problem. The best excipient strategy is therefore product-specific: minimal excipients for injection, palatability and age-appropriate safety for oral liquid, and validated delivery performance for any topical or device-enabled product.
Key Takeaways
- Aminocaproic acid is a mature generic antifibrinolytic with little practical molecule-level exclusivity.
- Excipient selection is most important for oral palatability, pediatric safety, injectable compatibility, and shelf life.
- Ready-to-use injectables and unit-dose oral liquids offer stronger commercial differentiation than conventional tablets.
- Generic and price competition are high for standard products.
- Paragraph IV litigation risk is likely limited unless a later formulation or method patent is listed.
- The main barriers are sterile manufacturing, supply reliability, API quality, regulatory execution, and hospital distribution.
- Licensing value lies in formulation technology, delivery systems, manufacturing capacity, and market access rather than in the active ingredient.
FAQs
Is aminocaproic acid available as a preservative-free injection?
Preservative-free presentations may be available depending on the manufacturer and market. Product-specific labeling and inactive-ingredient information must be checked before clinical or commercial use.
Can aminocaproic acid be formulated as a pediatric oral liquid?
Yes. A pediatric liquid can use taste masking, sugar-free excipients, unit-dose packaging, and oral syringes. The formulation requires age-appropriate excipient assessment, stability testing, microbial-control validation, and regulatory review.
Is topical aminocaproic acid an FDA-approved product?
Topical use is not automatically covered by approval of an oral or injectable product. A topical product would require a route-specific regulatory basis, supported safety and quality data, and appropriate labeling.
Does aminocaproic acid have biosimilar competition?
No. Aminocaproic acid is a small-molecule drug, so competition occurs through generic drug pathways rather than the FDA biosimilar pathway.
What is the strongest patent strategy for a new aminocaproic acid product?
The strongest strategy would focus on a clinically useful formulation or delivery system with measurable advantages in stability, administration, tolerability, packaging, or manufacturing. Routine excipient substitutions are less likely to provide durable patent protection.
References
-
U.S. Food and Drug Administration. (n.d.). Aminocaproic acid injection prescribing information. FDA-approved labeling.
-
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/
-
U.S. Food and Drug Administration. (n.d.). Inactive ingredient database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm
-
United States Pharmacopeia. (2024). United States Pharmacopeia and National Formulary. U.S. Pharmacopeial Convention.
-
DailyMed. (n.d.). Aminocaproic acid drug labeling. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/
